Zobrazeno 1 - 9
of 9
pro vyhledávání: '"35"'
Autor:
John C. Ruckdeschel, P. Bonomi, Antonio C. Wolff, Donna Neuberg, David H. Johnson, David S. Ettinger, Robert L. Comis
Publikováno v:
Journal of Clinical Oncology. 13:1615-1622
PURPOSE A phase II study of ifosfamide, carboplatin, and prolonged oral administration of etoposide (ICE) in patients with untreated extensive-disease (ED) small-cell lung cancer (SCLC) was conducted to assess toxicities, response, and median surviva
Autor:
Martee L. Hensley, Jason A. Konner, David R. Spriggs, Alexia Iasonos, Paul Sabbatini, Katherine M. Bell-McGuinn, Scott R. Gerst, S. Pezzulli, Carol Aghajanian, Diana M. Grabon, William P. Tew, Howard T. Thaler
Publikováno v:
Journal of Clinical Oncology. 29:4662-4668
Purpose Intraperitoneal (IP) cisplatin and intravenous (IV) or IP paclitaxel constitute a standard therapy for optimally debulked ovarian cancer. Bevacizumab prolongs progression-free survival (PFS) when included in first-line IV chemotherapy. In thi
Autor:
Frank V. Fossella, Roy S. Herbst, Rebecca Paulus, Walter J. Curran, Hak Choy, Philip O. Doescher, George R. Blumenschein, Ritsuko Komaki, Maria Werner-Wasik, Francisco Robert
Publikováno v:
Journal of Clinical Oncology. 29:2312-2318
Purpose Non–small-cell lung cancer (NSCLC) commonly expresses the epidermal growth factor receptor (EGFR), which is associated with poor clinical outcome. Cetuximab is a chimerized monoclonal antibody that targets the EGFR and, in preclinical model
Autor:
Suzanne Berlin, Hang Lee, Neil S. Horowitz, Ursula A. Matulonis, Richard T. Penson, Modjulie A. King, Carolyn N. Krasner, Stephen A. Cannistra, Paul DiSilvestro, Don S. Dizon, Maria R. Roche, Susana M. Campos
Publikováno v:
Journal of Clinical Oncology. 28:154-159
Purpose New strategies are needed to improve outcomes for patients with advanced ovarian cancer. Bevacizumab is a recombinant humanized monoclonal antibody that neutralizes vascular endothelial growth factor but is associated with GI perforations (GI
Autor:
Dennis F. Moore, Primo N. Lara, Zelanna Goldberg, Quynh-Thu Le, John Crowley, James J. Moon, Mary W. Redman, Laurie E. Gaspar, Stephen K. Williamson, David R. Gandara
Publikováno v:
Journal of Clinical Oncology. 27:3014-3019
Purpose A SWOG pilot study (S0004) showed that tirapazamine (TPZ) when combined with concurrent chemoradiotherapy yielded a promising median survival of 22 months in limited-stage small-cell lung cancer (LSCLC). We report results of the phase II stud
Publikováno v:
Journal of Clinical Oncology. 23:6873-6880
Purpose Feasibility and activity of concurrent hyperfractionated radiotherapy (Hfx RT) and low-dose, daily carboplatin and paclitaxel were investigated in patients with early-stage (I/II) non–small-cell lung cancer in a phase II study. Patients and
Autor:
Bipinkumar Amin, Dvorit Samid, Luis A. Meza, William J. Gradishar, Todd Hill, Yin Miao Chen, Elyse E. Lower, P. Kelly Marcom
Publikováno v:
Journal of Clinical Oncology. 22:2321-2327
Purpose The goal of this multicenter, open-label phase II study was the clinical evaluation of combination therapy with the oral fluoropyrimidine capecitabine and the taxane paclitaxel in patients with metastatic breast cancer (MBC). Patients and Met
Autor:
M. R. Cooper, Karen H. Antman, Mark R. Green, Nicholas J. Vogelzang, James E. Herndon, Joseph M. Corson, L B Weissman
Publikováno v:
Journal of Clinical Oncology. 12:1436-1442
PURPOSE Folic acid antagonists are reported to have activity against mesothelioma. The Cancer and Leukemia Group B (CALGB) undertook this phase II study of the new antifolate, trimetrexate (TMTX), to evaluate its response rate and toxicity in chemoth
Autor:
R Grunewald, D Gravel, Martin N. Raber, W Satterlee, Shin Mineishi, James L. Abbruzzese, T Adams, E A Weeks, B Nowak, P Tarassoff
Publikováno v:
Journal of Clinical Oncology. 9:491-498
A novel deoxycytidine analog, gemcitabine (2',2'-difluorodeoxycytidine [dFdC]), has been studied in a phase I clinical and pharmacology trial. Doses ranging from 10 to 1,000 mg/m2 were administered over 30 minutes weekly times 3 weeks every 4 weeks.